| 72.91 -0.68 (-0.92%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 89.86  |
1-year : | 104.96 |
| Resists | First : | 76.94 |
Second : | 89.86 |
| Pivot price | 70.51 |
|||
| Supports | First : | 66.53 |
Second : | 60.1 |
| MAs | MA(5) : | 73.33 |
MA(20) : | 69.61 |
| MA(100) : | 107.52 |
MA(250) : | 116.9 |
|
| MACD | MACD : | -3.1 |
Signal : | -5.1 |
| %K %D | K(14,3) : | 73.6 |
D(3) : | 78.1 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 156 | Low : | 60.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TMDX ] has closed below upper band by 24.8%. Bollinger Bands are 64.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 75.08 - 75.49 | 75.49 - 75.83 |
| Low: | 70.35 - 70.85 | 70.85 - 71.27 |
| Close: | 72.14 - 72.92 | 72.92 - 73.56 |
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Fri, 12 Jun 2026
TMDX News | TRANSMEDICS GROUP INC (NASDAQ:TMDX) - ChartMill
Fri, 12 Jun 2026
Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) - GlobeNewswire
Tue, 09 Jun 2026
TransMedics: Why I'm Still Bullish After The Collapse (NASDAQ:TMDX) - Seeking Alpha
Thu, 04 Jun 2026
TransMedics Group, Inc. (TMDX) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow - Seeking Alpha
Thu, 28 May 2026
Reasons to Retain TransMedics Stock in Your Portfolio for Now - Yahoo Finance
Thu, 21 May 2026
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 35 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 108.8 (%) |
| Shares Short | 8,180 (K) |
| Shares Short P.Month | 7,610 (K) |
| EPS | 4.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.81 |
| Profit Margin | 27 % |
| Operating Margin | 7.6 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 45.2 % |
| Qtrly Rev. Growth | 21.2 % |
| Gross Profit (p.s.) | 10.87 |
| Sales Per Share | 18.39 |
| EBITDA (p.s.) | 3.62 |
| Qtrly Earnings Growth | -71.5 % |
| Operating Cash Flow | 220 (M) |
| Levered Free Cash Flow | 109 (M) |
| PE Ratio | 16.68 |
| PEG Ratio | 0 |
| Price to Book value | 5.27 |
| Price to Sales | 3.96 |
| Price to Cash Flow | 11.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|